Celgene well they appear to be a very indecsive company where Mesoblast is concerned....Celgene are more involved with Juno and bluebird in the CAR T cell therapy business
Well Celgene did ask for an extension of the option and they asked for an extension of the scope of the applications. So I don't think that's indecisive.
They could have wanted them for less than MSB is prepared to let them go for.
Or a third party bidding war.
But I am posting about the upside as it's a sadly neglected area...so many shorters onto MSB it's sad.
My view for what it's worth, page-9
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |